Alligator Bioscience Reports Incremental Overall Survival Benefit of Mitazalimab Combined with mFOLFIRINOX, Jan. 27, 2025
Alligator Bioscience (Sweden) reports new positive data showing an incremental overall survival benefit for mitazalimab when combined with mFOLFIRINOX. This was determined through a literature-based indirect comparison of outcomes.
Full Article: Alligator Bioscience Report
Merck’s Welireg Up for Potential FDA Label Expansion, Jan. 27, 2025
Merck (Global Pharma) is seeking a potential FDA label expansion for Welireg. The FDA has granted a priority review to the company's bid to expand the drug’s indications to include advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL).
Full Article: Merck’s Welireg
Innate Pharma Doses First Patient in Phase 1 Study of IPH4502, Jan. 27, 2025
Innate Pharma (Marseille, France) announces the first patient dosed in the Phase 1 study of its Nectin-4 targeting antibody-drug conjugate, IPH4502. The drug aims to treat a range of advanced solid tumors, including urothelial carcinoma, breast cancer, and non-small cell lung cancer.
Full Article: Innate Pharma Update
Leap Therapeutics Pauses Phase 3 in Gastric Cancer after Failed Mid-Stage Data, Jan. 28, 2025
Leap Therapeutics (Massachusetts, US) halts plans to progress into Phase 3 trials for gastric cancer after disappointing Phase 2b data. However, the company will continue to explore the potential of sirexatamab in colorectal cancer.
Full Article: Leap Therapeutics Update
ITM’s Lead Radiopharmaceutical Shows Positive Phase 3 Data in Neuroendocrine Tumors, Jan. 28, 2025
ITM Isotope Technologies Munich SE (Munich, Germany) announces that its lead radiopharmaceutical, ITM-11, outperformed the current standard of care at prolonging progression-free survival in a Phase 3 trial for inoperable neuroendocrine tumors.
Full Article: ITM Trial Results
FDA Approves Enhertu for HER2-Ultralow Breast Cancer, Jan. 28, 2025
AstraZeneca and Daiichi Sankyo (Global Pharma) announce the FDA’s approval of Enhertu for the treatment of HER2-ultralow breast cancer. The approval expands the drug's indications to include more aggressive breast cancers.
Full Article: FDA Approval for Enhertu
Ascentage Pharma Raises $126 Million in U.S. IPO, Jan. 28, 2025
Ascentage Pharma (China) successfully raised over $126 million in its U.S. IPO. The proceeds will help fund the development of its cancer drugs, including olverembatinib, which has been approved in China.
Full Article: Ascentage Pharma IPO
Zentalis Pharmaceuticals Announces Workforce Restructuring to Support Azenosertib Development, Jan. 28, 2025
Zentalis Pharmaceuticals (US) announces a strategic restructuring to support the late-stage development of its WEE1 inhibitor, azenosertib, with a workforce reduction to extend its cash runway.
Full Article: Zentalis Restructuring
Atara Biotherapeutics Announces Workforce Reduction after FDA Setbacks, Jan. 28, 2025
Atara Biotherapeutics (US) will cut 50% of its workforce following FDA rejections and a clinical hold on its applications. The company is exploring strategic alternatives, including potential mergers or asset sales.
Full Article: Atara Layoffs
I-MAB Lays Off 27% of Workforce After Pipeline Shift, Jan. 29, 2025
I-MAB (China) announces a 27% reduction in its workforce following a pipeline shift to focus on its CLDN18.2x4-1BB bispecific antibody. The company anticipates key data readouts in 2025.
Full Article: I-MAB Layoffs
CARGO Therapeutics to Discontinue Phase 2 Study of Firi-cel, Jan. 29, 2025
CARGO Therapeutics (US) discontinues the FIRCE-1 Phase 2 study of firi-cel in large B-cell lymphoma patients. The company will reduce its workforce by 50% and prioritize other programs.
Full Article: CARGO Therapeutics Update
OS Therapies Acquires Ayala Pharmaceuticals’ Immuno-Oncology Programs, Jan. 30, 2025
OS Therapies (US) acquires Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs, adding clinical-stage assets for lung and prostate cancer to its pipeline.
Full Article: OS Therapies Acquisition
Tubulis Initiates Clinical Trial for TUB-030 in Solid Tumors, Jan. 30, 2025
Tubulis (Germany) begins clinical evaluation of its next-generation ADC, TUB-030, targeting 5T4 in solid tumors. The Phase I/IIa trial aims to evaluate safety and efficacy in various cancer types.
Full Article: Tubulis Trial Update
Takeda CEO Christophe Weber Announces Retirement in 2026, Jan. 30, 2025
Takeda (Japan) announces CEO Christophe Weber’s plan to retire in 2026. Julie Kim, president of Takeda's U.S. business, will succeed him as CEO.
Full Article: Takeda Leadership Change
Kazia Therapeutics Launches Clinical Trial Evaluating Paxalisib Combination in Advanced Breast Cancer, Jan. 31, 2025
Kazia Therapeutics (Australia) launches the ABC-Pax trial, evaluating paxalisib in combination with Keytruda or Lynparza for triple-negative breast cancer.
Full Article: Kazia Clinical Trial Update
